Low-Level Laser Therapy for Hair Loss: What the 2025 Evidence Actually Shows

Low-level laser therapy, also called photobiomodulation, was FDA-cleared for androgenetic alopecia in 2007. In the nearly two decades since, a cottage industry of laser combs, helmets, caps, and bands has grown up around the technology, generating hundreds of millions in annual revenue. The claims range from modest to extraordinary. What does the rigorous clinical evidence actually show?

The biological mechanism is the most credible part. Photobiomodulation at wavelengths in the red and near-infrared range (typically 650–1200nm) is absorbed by cytochrome c oxidase, a component of the mitochondrial electron transport chain. This increases mitochondrial membrane potential and ATP production in cells that receive the light. In hair follicle cells, particularly dermal papilla cells, this appears to stimulate proliferative activity and reduce apoptosis. The mechanism is coherent and is consistent with the general biology of photobiomodulation in other contexts (wound healing, pain management, muscle recovery).

A 2025 systematic review in the British Journal of Dermatology identified 23 randomised controlled trials of LLLT for androgenetic alopecia, 15 of which were of adequate quality for pooled analysis. The meta-analytic effect: a mean increase of 9.6 hairs per cm² versus sham device, with a 95% confidence interval of 5.8 to 13.4. That's a statistically robust finding, heterogeneous across trials but consistently positive. Hair shaft calibre also improved, a mean increase of 6.1 micrometres in shaft diameter.

The comparison to pharmacological treatments matters for context. Minoxidil produces approximately 15–20 hairs/cm² in comparable studies. Finasteride produces 17–23 hairs/cm². LLLT's 9.6 hairs/cm² is roughly half the effect of established pharmacological treatments. It's not nothing, 9.6 additional hairs per cm² is visible in photography-based assessments and patient-reported as meaningful, but it's not equivalent to the drugs.

Where LLLT does compare favourably is safety. The 23 trials showed no serious adverse events attributable to device use. Mild scalp warmth and temporary redness were reported in roughly 8% of sessions. There are no systemic effects, no hormonal consequences, no interactions with medications. For patients who can't or won't take finasteride or dutasteride, which includes women of childbearing age, men concerned about sexual side effects, and anyone on contraindicated medications, LLLT is a legitimate option with a real evidence base.

The device quality variation is a serious practical concern that the review doesn't fully address. Not all laser devices are equivalent. Power output, wavelength, coverage area, and treatment duration all vary. Cheaper consumer devices may not deliver the fluence (energy per area) demonstrated to be effective in trials. The trials used medical-grade devices with verified output. The $200 laser cap purchased online may not. Patients should look specifically for devices that have FDA 510(k) clearance and whose trial data has been published in peer-reviewed literature, a much smaller category than the marketing landscape suggests.